| KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company. |
globenewswire.com |
2025-05-16 01:00:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results |
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026 Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA); Phase 2 MG data anticipated in 2H 2025 Company to host KOL event in Q3 2025, spotlighting its accelerating neuroinflammation franchise Strong financial position; cash runway into 2027 supports first BLA filing, MG Phase 3 trial and pre-launch activities EMERYVILLE, Calif. , May 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended March 31, 2025. |
prnewswire.com |
2025-05-13 20:02:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026 Clinical data in myasthenia gravis and lupus nephritis expected in 2H 2025 Strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts EMERYVILLE, Calif. , March 27, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the full year 2024. |
prnewswire.com |
2025-03-27 18:02:00 |
Czytaj oryginał (ang.) |
| Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 |
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026. |
seekingalpha.com |
2025-03-21 13:29:27 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference |
EMERYVILLE, Calif. , March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. |
prnewswire.com |
2025-03-03 18:05:00 |
Czytaj oryginał (ang.) |
| What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock |
Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-10 15:01:16 |
Czytaj oryginał (ang.) |
| Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=128046&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-07 18:30:00 |
Czytaj oryginał (ang.) |
| Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX |
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit. |
globenewswire.com |
2025-02-07 15:05:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127987&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-07 14:00:00 |
Czytaj oryginał (ang.) |
| KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit |
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the "IPO"), of the important February 7, 2025 lead plaintiff deadline. So what: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2025-02-07 13:42:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127966&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-07 13:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX) and reminds investors of the February 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. |
prnewswire.com |
2025-02-07 13:05:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127932&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-07 12:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX |
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-07 12:00:00 |
Czytaj oryginał (ang.) |
| Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127802&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-07 09:25:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO"). |
accessnewswire.com |
2025-02-07 09:00:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX |
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. |
prnewswire.com |
2025-02-07 07:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127730&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-06 21:45:00 |
Czytaj oryginał (ang.) |
| Shareholders that Lost Money on Kyverna Therapeutics, Inc. (KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127720&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-06 21:15:00 |
Czytaj oryginał (ang.) |
| February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - KYTX |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127681&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-06 18:30:00 |
Czytaj oryginał (ang.) |
| Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX |
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). |
globenewswire.com |
2025-02-06 15:51:00 |
Czytaj oryginał (ang.) |
| February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127637&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-06 14:30:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127624&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-06 14:00:00 |
Czytaj oryginał (ang.) |
| KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTX |
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-02-06 13:32:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127622&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-06 13:30:00 |
Czytaj oryginał (ang.) |
| ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KYTX |
NEW YORK, Jan. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-01-04 22:58:00 |
Czytaj oryginał (ang.) |
| February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX |
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120643&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-04 22:17:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc.(KYTX) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120622&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-04 20:01:00 |
Czytaj oryginał (ang.) |
| KYTX Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. |
RADNOR, Pa. , Jan. 4, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). |
prnewswire.com |
2025-01-04 17:28:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics Inc Is Being Sued For Securities Law Violations And Affected Investors Are Encouraged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025. |
accesswire.com |
2025-01-04 13:45:00 |
Czytaj oryginał (ang.) |
| KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX |
NEW ORLEANS , Jan. 3, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NasdaqGS: KYTX), if they purchased the Company's shares pursuant and/or traceable to the Company's registration statement issued in connection with its February 2024 initial public offering ("IPO"). |
prnewswire.com |
2025-01-04 00:50:00 |
Czytaj oryginał (ang.) |
| ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX |
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / WHY: New York, N.Y., January 3, 2025. |
accesswire.com |
2025-01-03 21:35:00 |
Czytaj oryginał (ang.) |
| Investors who Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky about Pending Class Action - KYTX |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120597&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 19:45:00 |
Czytaj oryginał (ang.) |
| Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120557&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 16:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accesswire.com |
2025-01-03 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120502&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 13:45:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc |
LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025. |
accesswire.com |
2025-01-03 13:30:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Kyverna Therapeutics, Inc. (KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120399&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 09:25:00 |
Czytaj oryginał (ang.) |
| KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO"). |
accesswire.com |
2025-01-03 09:00:00 |
Czytaj oryginał (ang.) |
| February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX |
NEW YORK , Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. |
prnewswire.com |
2025-01-03 07:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120375&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 02:15:00 |
Czytaj oryginał (ang.) |
| KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX |
NEW ORLEANS, LA / ACCESSWIRE / January 2, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NasdaqGS:KYTX), if they purchased the Company's shares pursuant and/or traceable to the Company's registration statement issued in connection with its February 2024 initial public offering ("IPO"). |
accesswire.com |
2025-01-02 19:30:00 |
Czytaj oryginał (ang.) |
| Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120183&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-02 15:00:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact The Gross Law Firm about pending Class Action - KYTX |
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-01-02 14:50:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX |
NEW YORK, NY / ACCESSWIRE / January 1, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120023&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-02 14:00:00 |
Czytaj oryginał (ang.) |